TrialTargeted oncology2021
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
Ying Cheng et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
113 papers cite itlatest 60 shown
this paperpooled ittrialcites it